The foundation behind Novo Nordisk, which makes weight-loss drugs Ozempic and Wegovy, will invest €80 million ($93 million) ...

After sharing the herbs he includes in his diet and the snacks he eats for energy, Harvard-trained gastroenterologist Dr ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Hims & Hers Health, Inc. (NYSE: HIMS) between April 29, 2025 and June 23, 2025, both dates inclusive (the ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

House deals a blow to “Crypto Week,” ASML warns on 2026 growth, a promising Chinese weight-loss drug, and more news to start your day.

Biocon aims to launch generic copies of the blockbuster weight-loss drug Wegovy in India and Canada within the next two years ...

There's nothing preventing patients from lying when asked about eating disorders as part of the telehealth screening and ...

In 2023, 32.69 per cent of adults in Canada (10.6 million people) were overweight with a Body-Mass Index (BMI) of 30 or ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

STORY: "Absolutely unacceptable and unjustified."That was the reaction from EU ministers to a 30% tariff on European goods ...

Hengrui has reported topline data from the 301 study of their dual GLP-1 and GIP agonist HRS9531, administered as a ...

By Mariam Sunny (Reuters) -U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body ...